PDRadiopharma Submits Partial Change Application for Additional Indication of Raiatt MIBG-I131 for Neuroblastoma

Further Enhancements Added to the “onti” Medical Isotope Exposure Dose Management System

PDRadiopharma Host Joint Seminar at The 84th Annual Meeting of the Japanese Society, and Exhibit at the International Technical Exhibition of Medical Imaging 2025

New Radiopharmaceuticals for Renal Cell Carcinoma -Assessing the potential of PD-32766 as a PET diagnostic and raising expectations for novel diagnostic and therapeutic agents in nuclear medicine-（National Cancer Center／PeptiDream Inc.）

Announcement of New Management Structure